Abstract
Propofol (2,6-diisopropylphenol) is administered intravenously for induction and maintenance of anesthesia; however, progressive myocardial failure (propofol syndrome) has been reported. In the present study, the individual differences in pharmacokinetics and/or pharmacodynamics of propofol were investigated in patients who were genotyped for CYP2B6 and UGT1A9. Fifty-one patients treated with propofol in St. Marianna University Hospital were recruited for this study and provided written informed consent. The following parameters were analyzed: awakening time as a pharmacodynamic parameter, duration of propofol infusion, drug concentration in plasma after treatment, genotypes of CYP2B6 and UGT1A9, and age (42–84 years, mean of 65 years). Propofol was rapidly cleared from the blood of the subjects as a result of distribution and elimination phase. The awakening time after stopping propofol infusion was significantly correlated with the duration of infusion and maximum concentration of propofol in these subjects. The maximum plasma concentration of propofol after normalizing with the duration of infusion was affected by the CYP2B6 G516T variant (related to impaired function) and was significantly affected by a propofol risk index scores incorporating CYP2B6 G516T and UGT1A9 I399C>T (high expression) genotypes and advanced age. These results provide important information for two enzyme genotypes and advanced age as combinative determinant factors of the pharmacokinetics and/or pharmacodynamics of propofol.
